Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM035
MIFTS: 48

Pulmonary Eosinophilia

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Eosinophilia

About this section

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 54 15 71
Asthmatic Pulmonary Eosinophilia 71

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 34 518.3
MeSH 43 D011657
SNOMED-CT 67 91053000
ICD10 32 J82
UMLS 71 C0034068 C0340076
Sources

Summaries for Pulmonary Eosinophilia

About this section
Disease Ontology : 12 A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to loeffler syndrome and chronic eosinophilic pneumonia, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 loeffler syndrome 33.6 PRG2 IL5 IL13
2 chronic eosinophilic pneumonia 33.3 RNASE3 IL5 CCL5 CCL3 CCL11
3 ascaris lumbricoides infection 32.1 IL5 IL13 CXCL8
4 eosinophilic pneumonia 31.2 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
5 filarial elephantiasis 30.7 IL5 IL4 IL13
6 elephantiasis 30.6 RNASE3 IL5 IL4
7 cytokine deficiency 30.4 IL5 IL13
8 folliculitis 30.0 IL5 IL4 CCL5 CCL11
9 respiratory syncytial virus infectious disease 29.9 IL5 IL13 CCL5 CCL3
10 pneumoconiosis 29.5 SERPINA1 IL4 CXCL8
11 leprosy 3 29.5 IL5 IL4 CXCL8 CSF2
12 sarcoidosis 1 29.4 SFTPD IL13 CCL5 CCL3
13 idiopathic interstitial pneumonia 29.3 SFTPD IL4 IL13 CXCL8
14 bronchiolitis obliterans 29.3 SFTPD IL13 CXCL8
15 pulmonary fibrosis 29.0 SFTPD IL13 CXCL8 CCL3 CCL17
16 churg-strauss syndrome 28.8 RNASE3 PRG2 IL5 CYSLTR1 CXCL8 CCL17
17 allergic bronchopulmonary aspergillosis 28.6 SFTPD IL5 IL4 EPX CCR3 CCL17
18 allergic asthma 28.5 RNASE3 IL5 IL4 IL13 EPX CXCL8
19 interstitial lung disease 28.4 SFTPD IL5 IL4 IL13 CXCL8 CSF2
20 bronchiolitis 28.3 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
21 dermatitis 28.2 RNASE3 IL5 IL4 IL13 CXCL8 CSF2
22 aspergillosis 28.2 SFTPD IL5 IL4 EPX CXCL8 CSF2
23 hypereosinophilic syndrome 28.1 RNASE3 PRG2 IL5 IL4 IL13 EPX
24 bronchitis 28.1 SERPINA1 RNASE3 IL5 IL4 IL13 CXCL8
25 respiratory failure 27.2 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL13
26 pneumonia 27.1 SFTPD SERPINA1 IL5 IL4 IL13 CXCL8
27 lung disease 26.9 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL4
28 rhinitis 26.8 RNASE3 PRG2 IL5 IL4 IL13 EPX
29 allergic rhinitis 26.8 RNASE3 IL5 IL4 IL13 EPX CXCL8
30 allergic hypersensitivity disease 24.8 SFTPD RNASE3 PRG2 IL5 IL4 IL13
31 asthma 24.0 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 PDE4A
32 idiopathic eosinophilic pneumonia 10.9
33 idiopathic acute eosinophilic pneumonia 10.8
34 aztreonam allergy 10.5 IL5 IL13
35 ceftriaxone allergy 10.5 IL5 IL13
36 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL5 IL13
37 cefaclor allergy 10.5 IL5 IL13
38 allergic encephalomyelitis 10.5 CCL5 CCL3
39 cefuroxime allergy 10.5 IL5 IL13
40 whiplash 10.4 CCL5 CCL3
41 adhesive otitis media 10.4 RNASE3 CCL11
42 norwegian scabies 10.4 IL5 IL13
43 pemphigoid gestationis 10.4 RNASE3 IL5 CCL11
44 cough variant asthma 10.4 RNASE3 IL5 IL4
45 nickel allergic contact dermatitis 10.4 IL5 IL4
46 nut allergy 10.4 IL5 IL4 IL13
47 toxic oil syndrome 10.4 IL5 IL4
48 cow milk allergy 10.4 RNASE3 IL5 IL4
49 strongyloidiasis 10.4 IL5 IL13 CCL11
50 filariasis 10.4

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia
Sources

Symptoms & Phenotypes for Pulmonary Eosinophilia

About this section

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCL11 CCL17 CCL5 CCR3 CSF2 EPX
2 immune system MP:0005387 9.77 CCL11 CCL17 CCL5 CCR3 CSF2 CYSLTR1
3 respiratory system MP:0005388 9.28 CCL11 CCR3 CSF2 CYSLTR1 IL13 IL4
Sources

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
8
Omalizumab Approved, Investigational Phase 4 242138-07-4
9 Benralizumab Approved, Investigational Phase 4 1044511-01-4
10
Budesonide Approved Phase 4 51333-22-3 63006 5281004
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Antiemetics Phase 4
13 Methylprednisolone Acetate Phase 4
14 Gastrointestinal Agents Phase 4
15 Neuroprotective Agents Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Anti-Allergic Agents Phase 4
18 Hormone Antagonists Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Autonomic Agents Phase 4
21 glucocorticoids Phase 4
22 Hormones Phase 4
23 Neurotransmitter Agents Phase 4
24 Adrenergic Agonists Phase 4
25 Adrenergic beta-Agonists Phase 4
26 Tocolytic Agents Phase 4
27 Adrenergic Agents Phase 4
28 Bronchodilator Agents Phase 4
29 Albuterol Phase 4
30 Formoterol Fumarate Phase 4
31 Budesonide, Formoterol Fumarate Drug Combination Phase 4
32
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
33 Reslizumab Approved, Investigational Phase 3
34 Immunoglobulin G Phase 3
35 Pharmaceutical Solutions Phase 3
36 Antineoplastic Agents, Immunological Phase 2, Phase 3
37 Immunologic Factors Phase 3
38 Antibodies, Monoclonal Phase 3
39 Immunoglobulins Phase 3
40 Antibodies Phase 3
41
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
42
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
43
Pramipexole Approved, Investigational Phase 2 104632-26-0 59868 119570
44 Indoleacetic Acids Phase 2
45 Sympathomimetics Phase 2
46
Salmeterol xinafoate Phase 2 94749-08-3 56801
47 Dermatologic Agents Phase 2
48 Fluticasone-Salmeterol Drug Combination Phase 2
49 Protective Agents Phase 2
50 Dopamine Agents Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
3 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
5 SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Not yet recruiting NCT04159519 Phase 4 Symbicort®;Fasenra®;Ventolin®
6 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
7 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
8 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
9 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
10 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
11 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
12 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
13 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
14 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
15 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
16 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
17 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
18 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
19 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
20 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
21 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
22 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Recruiting NCT04046939 Phase 2 low-dose dexpramipexole;mid-dose dexpramipexole;high-dose dexpramipexole;placebo oral tablet
23 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
24 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
25 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
26 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
27 imPROve-asthma - A Prospective, 12-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany Recruiting NCT04184284
28 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
29 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
30 Effects of Anti-IL5 Biological Treatments of Total Blood IgE Levels in Severe Asthmatic Patients: Real-life Retrospective Multicenter Observational Study Recruiting NCT04181190
31 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
32 A Multicentre, Single Arm, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Eosinophilic Asthma Patients Older Than 18 Starting Benralizumab in Switzerland Recruiting NCT03907137
33 A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Recruiting NCT03733535 Benralizumab;129 Xenon
34 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab
35 Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece Active, not recruiting NCT04084613
36 Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Not yet recruiting NCT04126499
37 Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting Not yet recruiting NCT04187976

Search NIH Clinical Center for Pulmonary Eosinophilia

Sources

Genetic Tests for Pulmonary Eosinophilia

About this section
Sources

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

40
Lung, T Cells, Bone, Heart, Testes, Bone Marrow, Neutrophil
Sources

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 773)
# Title Authors PMID Year
1
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. 54 61
17996260 2008
2
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. 54 61
17940489 2007
3
Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). 54 61
16120093 2005
4
Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. 54 61
16014847 2005
5
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. 54 61
15905537 2005
6
Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. 54 61
15158774 2004
7
Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. 54 61
12871220 2003
8
Elevated immunoglobulin E against recombinant Brugia malayi gamma-glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity. 54 61
12540554 2003
9
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. 54 61
11713356 2001
10
Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. 54 61
11740726 2001
11
Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. 54 61
11046102 2000
12
Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. 54 61
10753501 2000
13
Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. 54 61
10590259 1999
14
Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. 54 61
10030835 1999
15
An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. 54 61
9712797 1998
16
IgE down regulation and cytokine induction by Aspergillus antigens in human allergic bronchopulmonary aspergillosis. 54 61
9523846 1998
17
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. 54 61
9802959 1998
18
Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. 54 61
9032176 1997
19
Cytokines as targets for the inhibition of eosinophilic inflammation. 54 61
9352584 1997
20
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. 54 61
8985399 1997
21
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. 54 61
8818342 1996
22
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. 54 61
8784786 1996
23
Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. 54 61
8627493 1996
24
Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. 54 61
8664444 1995
25
Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. 54 61
7613159 1995
26
Animal models of occupational asthma. 54 61
8013613 1994
27
Allergic bronchopulmonary mycosis complicating cystic fibrosis. 54 61
1475542 1992
28
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. 54 61
2010556 1991
29
Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. 54 61
1899687 1991
30
The BALB/c mouse as a model for immunological studies of microfilariae-induced pulmonary eosinophilia. 54 61
2382764 1990
31
Unexpected Outcome of Daptomycin-induced Eosinophilic Pneumonia: Rarity Within a Rarity. 61
31903307 2019
32
A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. 61
31744552 2019
33
CD200R1 regulates eosinophilia during pulmonary fungal infection in mice. 61
31365119 2019
34
Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease. 61
31075351 2019
35
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. 61
29969926 2019
36
Diagnostic pitfalls of acute eosinophilic pneumonia in an adolescent boy following cigarette smoking: A case report. 61
31096462 2019
37
Cigarette smoking-induced acute eosinophilic pneumonia: A case report. 61
30817609 2019
38
Filarial tropical pulmonary eosinophilia. 61
30720371 2019
39
Extracorporeal Membrane Oxygenation in Severe Acute Eosinophilic Pneumonia. 61
31024915 2019
40
TNF-α-Producing Cryptococcus neoformans Exerts Protective Effects on Host Defenses in Murine Pulmonary Cryptococcosis. 61
31404168 2019
41
Elevated Periostin Concentrations in the Bronchoalveolar Lavage Fluid of Patients with Eosinophilic Pneumonia. 61
30612125 2019
42
[Vasculitides and eosinophilic pulmonary diseases]. 61
30367242 2018
43
Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. 61
29428392 2018
44
Anti-Inflammatory Activities of Pentaherbs formula and Its Influence on Gut Microbiota in Allergic Asthma. 61
30373169 2018
45
BMS‑345541 inhibits airway inflammation and epithelial‑mesenchymal transition in airway remodeling of asthmatic mice. 61
30015827 2018
46
Inception of early-life allergen-induced airway hyperresponsiveness is reliant on IL-13+CD4+ T cells. 61
30194239 2018
47
[Vasculitides and eosinophilic pulmonary diseases]. 61
30140942 2018
48
Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia. 61
29803709 2018
49
Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. 61
28488945 2018
50
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. 61
29319845 2018
Sources

Variations for Pulmonary Eosinophilia

About this section
Sources

Expression for Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.
Sources

Pathways for Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.97 SERPINA1 RNASE3 RNASE2 PRG2 IL5 IL4
2
ERK Signaling 63
Show member pathways
 13.77 PRG2 IL5 IL4 IL13 CXCL8 CSF2
3
PEDF Induced Signaling 63
Show member pathways
 13.62 IL5 IL4 IL13 CXCL8 CSF2 CCR3
4
TGF-Beta Pathway 63
Show member pathways
 13.52 IL5 IL4 IL13 CXCL8 CCL7 CCL5
5
Integrin Pathway 63
Show member pathways
 13.38 PRG2 CXCL8 CCR3 CCL7 CCL5 CCL3
6
Akt Signaling 63
Show member pathways
 13.34 IL5 IL4 IL13 CXCL8 CSF2 CCR3
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 IL5 IL4 IL13 CXCL8 CSF2 CCL5
8
PAK Pathway 63
Show member pathways
 13.17 IL5 IL4 IL13 CXCL8 CSF2 CCR3
9
Human cytomegalovirus infection 36
Show member pathways
 12.85 CXCL8 CSF2 CCR3 CCL5 CCL3
10
CCR5 Pathway in Macrophages 63
Show member pathways
 12.85 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
11
Allograft rejection 1 36
Show member pathways
 12.82 RNASE3 PRG2 IL5 IL4 IL13 EPX
12
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.33 CXCL8 CCR3 CCL7 CCL5 CCL11
13
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.31 IL5 IL4 IL13 CSF2
14
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.28 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
15
IL-17 Family Signaling Pathways 64
Show member pathways
 12.26 IL5 IL4 IL13 CXCL8 CSF2 CCL7
16
Bacterial infections in CF airways 22
Show member pathways
 12.16 SFTPD IL4 CXCL8 CCL11
17
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.98 IL5 IL4 CSF2 CCR3
18
Interleukin-4 and 13 signaling 65
11.97 IL4 IL13 CXCL8 CCL11
19
Rheumatoid arthritis 36
11.87 CXCL8 CSF2 CCL5 CCL3
20
Hematopoietic cell lineage 36
11.83 IL5 IL4 CSF2
21
Glucocorticoid receptor regulatory network 1
11.81 IL5 IL4 IL13 CXCL8 CSF2
22
Innate Lymphoid Cell Differentiation Pathways 64
11.79 IL5 IL4 IL13 CCL3
23
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.76 IL5 IL4 CXCL8 CSF2
24
Salmonella infection (KEGG) 36
11.73 CXCL8 CSF2 CCL3
25
IL4-mediated signaling events 1
11.66 IL5 IL4 CCL17 CCL11
26
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.55 IL4 IL13 CSF2 CCL5 CCL3 CCL17
27
Th2 Differentiation Pathway 64
11.49 IL5 IL4 IL13 CCL17 CCL11
28
Interleukin-10 signaling 65
11.42 IL4 IL13 CXCL8 CSF2 CCL5 CCL3
29
Development and heterogeneity of the ILC family 1
11.31 IL5 IL4 IL13
30
Cytokines and Inflammatory Response 1
11.27 IL5 IL4 IL13 CSF2
31
OX40 Pathway 63
11.2 IL5 IL4 IL13
32
Lung fibrosis 1
11.12 SERPINA1 IL5 IL4 IL13 CXCL8 CSF2
33
G-protein signaling_Rap2B regulation pathway 22
10.6 PRG2 IL5 IL4 IL13 CXCL8 CSF2
Sources

GO Terms for Pulmonary Eosinophilia

About this section

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 SFTPD SERPINA1 RNASE3 IL5 IL4 IL13
2 cell GO:0005623 9.7 IL13 CYSLTR1 CCR3 CCL7 CCL5 CCL3
3 extracellular region GO:0005576 9.53 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 IL5

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 PDE4A IL5 IL4 CYSLTR1 CXCL8 CCR3
2 G protein-coupled receptor signaling pathway GO:0007186 10.2 PDE4A CYSLTR1 CXCL8 CCR3 CCL7 CCL5
3 neutrophil degranulation GO:0043312 10.02 SERPINA1 RNASE3 RNASE2 PRG2 EPX
4 positive regulation of GTPase activity GO:0043547 10.01 CCL7 CCL5 CCL3 CCL17 CCL11
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 CCL7 CCL5 CCL3 CCL17 CCL11
6 cellular response to tumor necrosis factor GO:0071356 9.95 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
7 defense response to bacterium GO:0042742 9.94 SFTPD RNASE3 PRG2 EPX
8 MAPK cascade GO:0000165 9.93 IL5 CSF2 CCL5 CCL3
9 positive regulation of cell migration GO:0030335 9.93 CCL7 CCL5 CCL3 CCL11
10 cell-cell signaling GO:0007267 9.92 CCL7 CCL5 CCL3 CCL17
11 cytokine-mediated signaling pathway GO:0019221 9.92 IL5 IL4 IL13 CXCL8 CSF2 CCL5
12 cellular response to interferon-gamma GO:0071346 9.91 CCL7 CCL5 CCL3 CCL17 CCL11
13 inflammatory response GO:0006954 9.91 IL5 IL13 CXCL8 CCR3 CCL7 CCL5
14 cellular calcium ion homeostasis GO:0006874 9.89 CCL7 CCL5 CCL3 CCL11
15 neutrophil chemotaxis GO:0030593 9.88 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 IL4 IL13 CSF2 CCL5
17 monocyte chemotaxis GO:0002548 9.85 CCL7 CCL5 CCL3 CCL17 CCL11
18 cellular response to interleukin-1 GO:0071347 9.85 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
19 cell chemotaxis GO:0060326 9.83 CCR3 CCL5 CCL3
20 lymphocyte chemotaxis GO:0048247 9.83 CCL7 CCL5 CCL3 CCL17 CCL11
21 calcium-mediated signaling GO:0019722 9.81 CXCL8 CCR3 CCL3
22 eosinophil chemotaxis GO:0048245 9.8 CCL7 CCL5 CCL3 CCL11
23 positive regulation of B cell proliferation GO:0030890 9.78 IL5 IL4 IL13
24 macrophage chemotaxis GO:0048246 9.73 SFTPD CCL5 CCL3
25 induction of bacterial agglutination GO:0043152 9.71 SFTPD RNASE3 RNASE2
26 positive regulation of natural killer cell chemotaxis GO:2000503 9.7 CCL7 CCL5 CCL3
27 chemokine-mediated signaling pathway GO:0070098 9.7 CXCL8 CCR3 CCL7 CCL5 CCL3 CCL17
28 dendritic cell differentiation GO:0097028 9.67 IL4 CSF2
29 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.66 CXCL8 CCL5
30 positive regulation of podosome assembly GO:0071803 9.65 IL5 CSF2
31 negative regulation by host of viral transcription GO:0043922 9.65 CCL5 CCL3
32 neutrophil activation GO:0042119 9.65 CXCL8 CCL5
33 chemotaxis GO:0006935 9.61 RNASE2 CYSLTR1 CXCL8 CCR3 CCL7 CCL5
34 negative regulation of complement-dependent cytotoxicity GO:1903660 9.6 IL4 IL13
35 immune response GO:0006955 9.4 PRG2 IL5 IL4 IL13 CXCL8 CSF2

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.55 CCL7 CCL5 CCL3 CCL17 CCL11
2 lipopolysaccharide binding GO:0001530 9.54 SFTPD RNASE3 RNASE2
3 phospholipase activator activity GO:0016004 9.43 CCL5 CCL3
4 CCR1 chemokine receptor binding GO:0031726 9.43 CCL7 CCL5 CCL3
5 chemokine activity GO:0008009 9.43 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
6 CCR5 chemokine receptor binding GO:0031730 9.4 CCL5 CCL3
7 CCR4 chemokine receptor binding GO:0031729 9.32 CCL5 CCL17
8 cytokine activity GO:0005125 9.32 IL5 IL4 IL13 CXCL8 CSF2 CCL7
Sources

Sources for Pulmonary Eosinophilia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....